Geneva/Kinshasa — In a significant step against the deadliest Ebola outbreak in the Democratic Republic of the Congo’s history, World Health Organization expert groups on 4 November 2026 recommended adding two new vaccine candidates specifically designed for the Bundibugyo virus to the ongoing Tumaini clinical trial. The decision comes as the epidemic, declared in May 2026 and classified as a Public Health Emergency of International Concern, has surpassed 10,500 confirmed cases and more than 5,100 deaths in the DRC alone, with limited cross-border spread and sustained global surveillance.
The two candidates—ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, and Moderna’s mRNA-1469—will join the trial after national regulatory approvals. This marks the first time vaccines tailored to Bundibugyo virus disease (BVD) will be evaluated during an active outbreak of that specific strain. The Tumaini trial (“hope” in Swahili), launched in late October 2026 in the epicentre of Ituri province, initially began testing the licensed Ervebo vaccine, which targets the more common Zaire ebolavirus and has shown some potential for cross-protection. Four vaccination rings are already operational, focusing on contacts of confirmed cases or those who died from the disease, with additional rings in preparation.
WHO Director-General Tedros Adhanom Ghebreyesus emphasised the scientific progress while underscoring the limits of medical tools alone. “Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials, and trusted engagement with communities,” he told reporters. The DRC’s Institut National de Recherche Biomédicale is leading the trial with support from WHO, the University of Antwerp, Epicentre, Médecins Sans Frontières, the Institute of Tropical Medicine of Antwerp, and the Africa Centres for Disease Control and Prevention. Funding support from the Coalition for Epidemic Preparedness Innovations has accelerated the candidates’ readiness. Interim results are anticipated in early 2027.
A Rapidly Expanding Epidemic
The outbreak of Bundibugyo virus disease was first confirmed in mid-May 2026 in eastern DRC, with simultaneous detections in Uganda. Unlike previous outbreaks driven primarily by Zaire ebolavirus, this epidemic is fueled by the rarer Bundibugyo strain, for which no licensed vaccine or specific treatment existed at the outset. By early November 2026, official figures showed approximately 10,500 to 10,700 confirmed cases and more than 5,100 deaths in the DRC, yielding a case fatality ratio near 49–50 per cent. Ituri province remains the hardest hit, accounting for the majority of cases, followed by North Kivu and other areas across eight provinces: Ituri, Nord-Kivu, Sud-Kivu, Tshopo, Haut-Uélé, Bas-Uélé, Sud-Ubangi, and Nord-Ubangi.
This is the DRC’s 17th recorded Ebola outbreak and its largest by far. It ranks as the second-largest globally after the 2014–2016 West Africa epidemic. Transmission has been unusually rapid; the outbreak surpassed 1,000 cases far faster than the 2018 DRC outbreak. Roughly one-third of deaths have involved children, with particularly high fatality among those under five. Challenges include ongoing conflict and insecurity in eastern regions, remote and densely populated areas, high population mobility, and difficulties in access that have complicated contact tracing and response logistics.
Limited international spread has occurred. Uganda reported about 20 cases (mostly imported) before declaring the outbreak over in mid-2026. Kenya confirmed nine cases and two deaths linked to a traveller from the DRC via Uganda, with the last reported case in late October. Nigeria recorded one imported case in Abuja in a person with travel history involving Uganda; that patient was medically evacuated to Switzerland. One case was also managed in France earlier in the outbreak. Health authorities in these countries have conducted extensive contact tracing, and secondary transmission has remained limited.
Vaccine and Treatment Research Advances
The absence of a Bundibugyo-specific vaccine created an urgent research priority. Ervebo, proven highly effective against Zaire ebolavirus during the West Africa outbreak and subsequent DRC responses, entered the Tumaini trial first under a ring-vaccination design that prioritises high-risk contacts. The addition of the Oxford/Serum Institute ChAdOx1 and Moderna mRNA candidates expands the scientific inquiry. Preclinical data, including animal challenge studies in ferrets and non-human primates, plus early-phase human safety and immunogenicity results, supported the WHO Technical Advisory Group on Candidate Vaccines Prioritisation recommendation. Both candidates induced antibody responses relatively quickly and showed acceptable safety profiles in preliminary data.
Parallel progress is underway on therapeutics. The WHO-sponsored PARTNERS trial, launched in July 2026, is evaluating the monoclonal antibody MBP134, the antiviral remdesivir, and a combination of both for improving survival among patients with confirmed Bundibugyo virus disease. Supportive care remains the cornerstone of treatment: rapid isolation, fluid and electrolyte management, and management of complications. Expansion of treatment capacity has been a focus of the response, with more than 2,000 beds reported available at points and recovery numbers climbing into the thousands.
Response Challenges and Community Dimensions
Responders face a complex operating environment. Insecurity has restricted access to some health zones. Contact-tracing ratios have sometimes fallen short of targets, laboratory confirmation of alerts has lagged ideal levels in places, and a significant share of deaths has occurred outside treatment centres. Safe and dignified burial teams have not covered every affected zone equally. Community engagement remains critical; distrust, rumour, and practical barriers can hinder early care-seeking and acceptance of isolation or vaccination. Health workers have reported strains including equipment shortages and payment delays in some areas.
Despite these obstacles, progress is visible. Diagnostic capacity has expanded with additional laboratories. Treatment centres have improved quality of care. Thousands of survivors have recovered, and daily monitoring of tens of thousands of contacts continues. WHO and partners have repeatedly stressed that sustained, high-intensity implementation of classic public-health measures—case finding, isolation, contact follow-up, and community trust-building—is essential while vaccine and treatment data mature.
Global Risk Assessment and Preparedness
WHO and partner agencies assess the overall risk as very high within the DRC, high for neighbouring countries with land borders or strong travel links, and low for the rest of the African region and the wider world, including Europe and North America. Nonetheless, the potential for further international spread via travel remains under active monitoring. Several countries have strengthened airport and border screening, contact-tracing protocols for travellers from affected areas, and laboratory readiness. The United States and others have issued travel-related advisories or attestation requirements for passengers with recent presence in the DRC.
Africa CDC and WHO launched a joint continental preparedness and response plan earlier in the outbreak, seeking substantial funding to bolster detection, response, and readiness across the continent. European health authorities, including the European Centre for Disease Prevention and Control, continue regular epidemiological updates and have supported partner countries with expertise. The event’s designation as a PHEIC in May 2026 triggered temporary recommendations under the International Health Regulations and heightened international coordination.
Historical Context and Scientific Lessons
Ebola virus disease outbreaks have occurred periodically in Central and West Africa since the first recognised outbreaks in 1976. Bundibugyo virus, first identified in Uganda in 2007, has caused fewer and smaller outbreaks than Zaire ebolavirus until now. The current epidemic’s scale and speed have tested response systems refined after the 2014–2016 West Africa crisis and subsequent DRC outbreaks. Those earlier experiences delivered the licensed Ervebo vaccine, improved case-management protocols, and the ring-vaccination trial methodology now applied in Tumaini. The rapid movement of two Bundibugyo-specific candidates into outbreak evaluation reflects investments in platform technologies (adenoviral vectors and mRNA) and epidemic preparedness financing made in the intervening years.
Scientists note that generating efficacy data during an active outbreak is both ethically complex and scientifically valuable. The multi-candidate design of Tumaini allows simultaneous evaluation under a single framework, potentially accelerating policy decisions if one or more products demonstrate clear benefit. Results expected in early 2027 could inform both the current response and future preparedness for this and related filoviruses.
Outlook
Health officials stress that the outbreak remains far from over. Transmission continues in multiple DRC provinces, and any relaxation of control measures risks resurgence. The addition of targeted vaccine candidates to the clinical trial offers a concrete path toward additional tools, yet classical public-health interventions will determine the trajectory in the near term. Sustained political commitment, secure access to affected communities, adequate financing, and transparent community engagement will be decisive.
International partners continue to monitor the situation closely. While the risk of widespread global spread is currently assessed as low, the speed of this outbreak and the absence of a fully matched licensed vaccine until trial data emerge underscore the importance of vigilance, rapid information sharing, and investment in medical countermeasures. The Tumaini trial and the PARTNERS treatment study represent tangible expressions of scientific collaboration under crisis conditions. Their outcomes, expected over the coming months, will shape both the remaining course of this epidemic and the world’s readiness for the next filovirus threat.
As of early November 2026, the focus remains dual: implementing every available control measure at full intensity while accelerating the generation of evidence on vaccines and treatments that could finally match the Bundibugyo virus on equal terms. The coming weeks and months will test whether the combination of operational response and scientific advance can bring this record outbreak under control.
